XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Fundamental Analysis
USA - NASDAQ:XERS - US98422E1038 - Common Stock
7.43 USD
-0.28 (-3.63%)
7.55 USD
+0.12 (+1.62%)
Overall XERS gets a fundamental rating of 3 out of 10. We evaluated XERS against 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of XERS have multiple concerns. XERS is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
XERS had negative earnings in the past year.
In the past year XERS has reported a negative cash flow from operations.
XERS had negative earnings in each of the past 5 years.
In the past 5 years XERS always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -9.56%, XERS is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.56% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
XERS has a better Gross Margin (82.24%) than 86.98% of its industry peers.
XERS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for XERS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.24% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
2. Health
2.1 Basic Checks
XERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XERS has more shares outstanding
XERS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XERS is higher compared to a year ago.
2.2 Solvency
XERS has an Altman-Z score of 0.22. This is a bad value and indicates that XERS is not financially healthy and even has some risk of bankruptcy.
XERS has a Altman-Z score (0.22) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.22 |
ROIC/WACCN/A
WACC9.51%
2.3 Liquidity
A Current Ratio of 1.95 indicates that XERS should not have too much problems paying its short term obligations.
With a Current ratio value of 1.95, XERS is not doing good in the industry: 60.94% of the companies in the same industry are doing better.
A Quick Ratio of 1.24 indicates that XERS should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.24, XERS is not doing good in the industry: 68.75% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.95 | ||
| Quick Ratio | 1.24 |
3. Growth
3.1 Past
XERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.78%, which is quite impressive.
Looking at the last year, XERS shows a very strong growth in Revenue. The Revenue has grown by 23.89%.
XERS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 137.28% yearly.
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)23.89%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%37.06%
3.2 Future
XERS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.91% yearly.
The Revenue is expected to grow by 23.13% on average over the next years. This is a very strong growth
EPS Next Y93.29%
EPS Next 2Y56.04%
EPS Next 3Y42.72%
EPS Next 5Y34.91%
Revenue Next Year42.48%
Revenue Next 2Y30.98%
Revenue Next 3Y25.91%
Revenue Next 5Y23.13%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
XERS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
XERS is valuated quite expensively with a Price/Forward Earnings ratio of 44.96.
Based on the Price/Forward Earnings ratio, XERS is valued a bit cheaper than the industry average as 70.31% of the companies are valued more expensively.
XERS is valuated rather expensively when we compare the Price/Forward Earnings ratio to 32.68, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 44.96 |
4.2 Price Multiples
XERS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. XERS is cheaper than 75.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 512.16 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XERS's earnings are expected to grow with 42.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.04%
EPS Next 3Y42.72%
5. Dividend
5.1 Amount
No dividends for XERS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.43
-0.28 (-3.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners56.87%
Inst Owner Change0.39%
Ins Owners2.77%
Ins Owner Change0.67%
Market Cap1.20B
Revenue(TTM)203.07M
Net Income(TTM)-32.00M
Analysts85
Price Target9.18 (23.55%)
Short Float %11.53%
Short Ratio8.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.02%
Min EPS beat(2)-10.3%
Max EPS beat(2)64.35%
EPS beat(4)2
Avg EPS beat(4)21.95%
Min EPS beat(4)-19.83%
Max EPS beat(4)64.35%
EPS beat(8)4
Avg EPS beat(8)12.77%
EPS beat(12)7
Avg EPS beat(12)13.91%
EPS beat(16)9
Avg EPS beat(16)7.33%
Revenue beat(2)2
Avg Revenue beat(2)5.46%
Min Revenue beat(2)2.31%
Max Revenue beat(2)8.61%
Revenue beat(4)4
Avg Revenue beat(4)3.94%
Min Revenue beat(4)1.41%
Max Revenue beat(4)8.61%
Revenue beat(8)6
Avg Revenue beat(8)3.64%
Revenue beat(12)10
Avg Revenue beat(12)3.89%
Revenue beat(16)11
Avg Revenue beat(16)2.82%
PT rev (1m)0%
PT rev (3m)36.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)180%
EPS NY rev (1m)0%
EPS NY rev (3m)71.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 44.96 | ||
| P/S | 4.88 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 512.16 |
EPS(TTM)-0.1
EYN/A
EPS(NY)0.17
Fwd EY2.22%
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS1.52
BVpS-0.12
TBVpS-0.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.56% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.24% | ||
| FCFM | N/A |
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
F-Score5
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 79.73 | ||
| Cap/Depr | 4.77% | ||
| Cap/Sales | 0.24% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.95 | ||
| Quick Ratio | 1.24 | ||
| Altman-Z | 0.22 |
F-Score5
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)9.44%
Cap/Depr(5y)22.43%
Cap/Sales(3y)0.76%
Cap/Sales(5y)1.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y93.29%
EPS Next 2Y56.04%
EPS Next 3Y42.72%
EPS Next 5Y34.91%
Revenue 1Y (TTM)23.89%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%37.06%
Revenue Next Year42.48%
Revenue Next 2Y30.98%
Revenue Next 3Y25.91%
Revenue Next 5Y23.13%
EBIT growth 1Y73.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year223.57%
EBIT Next 3Y64.3%
EBIT Next 5Y46.27%
FCF growth 1Y77.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.06%
OCF growth 3YN/A
OCF growth 5YN/A
XERIS BIOPHARMA HOLDINGS INC / XERS FAQ
Can you provide the ChartMill fundamental rating for XERIS BIOPHARMA HOLDINGS INC?
ChartMill assigns a fundamental rating of 3 / 10 to XERS.
What is the valuation status for XERS stock?
ChartMill assigns a valuation rating of 3 / 10 to XERIS BIOPHARMA HOLDINGS INC (XERS). This can be considered as Overvalued.
How profitable is XERIS BIOPHARMA HOLDINGS INC (XERS) stock?
XERIS BIOPHARMA HOLDINGS INC (XERS) has a profitability rating of 2 / 10.
Can you provide the financial health for XERS stock?
The financial health rating of XERIS BIOPHARMA HOLDINGS INC (XERS) is 1 / 10.
Can you provide the expected EPS growth for XERS stock?
The Earnings per Share (EPS) of XERIS BIOPHARMA HOLDINGS INC (XERS) is expected to grow by 93.29% in the next year.